However, given that different breast and colorectal patient cancers upregulate the LILRB1 ligand HLA-G as a means of evading NK targeting and killing, LILRB1 is likely to be important in tumor immunity [52,53,54,55]. This evidence concerns the gene LILRB1 and neoplasm.